Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The impact of t(11;14) on treatment response & survival in multiple myeloma

Borja Puertas-Martinez • 25 Aug 2022
IMS 2022
Multiple Myeloma Venetoclax

Borja Puertas-Martinez, MD, University Hospital of Salamanca, Salamanca, Spain, comments on the impact of t(11;14) on treatment response & survival in patients with multiple myeloma in the era of novel agents. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Borja Puertas-Martinez

1:57
CAR-T in myeloma: will it provide a cure?
Borja Puertas-Martinez • 16 Feb 2024
4:49
CAR-T vs bispecifics in triple-class refractory multiple myeloma: comparing outcomes & sequencing
Borja Puertas-Martinez • 16 Feb 2024
6:38
Comparison of the safety & efficacy of CAR-T therapy vs bispecifics in R/R multiple myeloma
Borja Puertas-Martinez • 8 Oct 2022
1:51
GEMKyCyDex: KCyd vs Kd in patients with R/R multiple myeloma
Borja Puertas-Martinez • 25 Aug 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals